Journals / Tüberküloz ve Toraks / 2015 / Cilt: 63 - Sayı: 2

Acute exacerbation in COPD and asthma

KOAH ve astımda atak

Pages
111–131
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Specific treatments of the cause (infection, airpollution, pulmonary embolism etc.) should be administered.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic obstructive pulmonary disease (COPD) and asthma are airway diseases with acute exacerbations.
📊
Key Findings & Data:Smoking cessations, prevention of infections, long-acting anticholinergics, long-acting β2 agonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, mucolytics, prophilactic antibiotics can be effective on the prevention of COPD exacerbations.
💡
Conclusion & Impact:Specific treatments of the cause (infection, airpollution, pulmonary embolism etc.) should be administered.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic obstructive pulmonary disease (COPD) and asthma are airway diseases with acute exacerbations. Natural course of both disease are affected by exacerbations. COPD exacerbations may be caused by infections and other causes; indoor and outdoor pollution, cardiovascular diseases, asthma-COPD overlap syndrome, COPD- obstructive sleep apnea syndrome, pulmonary embolism, gastro-oesophageal reflux, anxiety-depression, pulmonary hypertension. Exposure to triggering factors, viral infections, treatment insufficiency may cause asthma exacerbations. Smoking cessations, prevention of infections, long-acting anticholinergics, long-acting β2 agonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, mucolytics, prophilactic antibiotics can be effective on the prevention of COPD exacerbations. Asthma exacerbations may be decreased by the avoidance of allergens, viral infections, occupational exposures, airpollution, treatment of comorbid diseases. Effective treatment of asthma is required to prevent asthma exacerbations. Inhaled steroids and combined treatments are the most effective preventive therapy for exacerbations. Patient education and cooperation is an element of the preventive measures for asthma attacks. Compliance to therapy, inhalation techniques, written asthma plans are required. The essential of COPD and asthma exacerbation treatment is bronchodilator therapy. Steroids are also implemented to the therapy, targeting the inflammation. Specific treatments of the cause (infection, airpollution, pulmonary embolism etc.) should be administered.

Özet

Kronik obstrüktif akciğer hastalığı (KOAH) ve astım, ataklarla seyreden hava yollarının hastalıklarıdır. Ataklar her iki hastalıkta da hastalığın doğal seyrini etkilemektedir. KOAH atakları infeksiyonlar ve infeksiyon dışı nedenlere bağlı olarak gelişebilir. İnfeksiyon dışınedenler; başlıca çevresel faktörler (iç ve dış ortam hava kirliliği, mevsimsel değişiklikler), kardiyovasküler hastalıklar, astım-KOAHoverlap sendrom varlığı, KOAH-obstrüktif uyku apne overlap sendrom varlığı, pulmoner emboli, gastro-özefageal reflü, anksiyetedepresyon, pulmoner hipertansiyon olması gibi diğer faktörlerdir. Astım atakları, tetikleyen etkenlere maruziyet, viral infeksiyonlar, tedavinin hasta veya hekim tarafından aksatılması veya yetersiz verilmesi ile ortaya çıkar. Sigaranın bırakılması, infeksiyonların önlenmesi, uzun etkili antikolinerjik, uzun etkili β2 agonist, inhaler kortikosteroidler, fosfodiesteraz-4 inhibitörleri, mukolitikler, profilaktik antibiyotikler KOAH akut ataklarının önlenmesinde etkili olabilir. Astımda tetikleyen allerjen, viral infeksiyonlardan korunma, mesleki ajanlar, çevre kirliliğinden sakınma, komorbit hastalıkların tedavisi ile atak oranlarında azalmalar sağlanabilmektedir. Etkin tedaviler verilmesi; inhaler steroidler ve kombine tedaviler atakların önlenmesinde en etkin tedavi ajanlarıdır. Hasta eğitimi ve hasta ile işbirliği; etkin bir tedavi verilerek hastaya düzgün tedavisinin kullanımının gereği, inhaler tekniği öğretilmeli ve eline yazılı eylem planı verilerek yakınmaları başlayınca yapması gerekenler yazılarak aktarılmalıdır. KOAH ve astım atak tedavisinin temeli yoğun bir bronkodilatör tedavidir. Buna paralel olarak, atakta yangıya yönelik steroid tedavileri de, hastanın durumuna göre, devreye sokulur. Ayrıca atağa neden olan soruna (infeksiyon, hava kirliliği, emboli vb.) özgül tedavi ve uygulanmalıdır.

🔖

Cite This Article

YORGANCIOĞLU, A., POLATLI, M., KIYAN, E., MUNGAN, D., BAVBEK, S., ŞEN, E., GEMİCİOĞLU, B., TÜRKTAŞ, H., YILDIRIM, N., DEMİR, T., ÇELİK, G. E., YILDIZ, F., SARYAL, S., GÜNEN, H., OĞUZÜLGEN, K., SAYINER, A. (2022). Acute exacerbation in COPD and asthma. Tüberküloz ve Toraks, Cilt: 63 - Sayı: 2, 111–131. https://ajindex.com/articles/618548

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Global Initiative for Chronic Obstructive Lung Disease. The Global Strategy for Diagnosis, management and Prevention of COPD (updated 2014, www.goldcopd.org)
  2. Caramori G, Contoli M, Marku B, Casolari P, Pauletti A, Forini G, et al. Definition and aetiology of infective exacerbations of COPD. Eur Respir Monogr 2013;60:58-67
  3. Reddel HK, Taylor DR, Bateman ED Boulet LP, Boushey HA, Busse WW. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009:1;180:59-99. doi: 10.1164/rccm.200801-060ST
  4. Montania D, Cavailles A, Bertoletti L, Botelhod A, Cortot A, Taillé C, et al. Adult asthma exacerbations in questions. Rev Mal Respir 2010:27:1175-94. doi: 10.1016/j.rmr.2010.10.005
  5. Global Strategy for Asthma Management and Prevention. Available at: http://www.ginasthma.org/local/uploads/ files/GINA_Report_2014_Jun11.pdf, (Last accessed on july 2014)
  6. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74
  7. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5
  8. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;9:CD007498. doi: 10.1002/14651858.CD007498.pub2
  9. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013;309:2353-61
  10. Polatli M, Cakir A, Cildag O, Bolaman AZ, Yenisey C, Yenicerioglu Y. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008;26:97-102
  11. Casanova C, Celli BR. Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD. Eur Respir J 2014;43:951-53. doi: 10.1183/09031936.00015614
  12. Romundstad S, Naustdal T, Romundstad PR, Sorger H, Langhammer A. COPD and microalbuminuria: a 12-year follow-up study. Eur Respir J 2014;43:1042-50
  13. Agusti A, Sin DD. Biomarkers in COPD. Clin Chest Med 2014;35:131-141. doi: 10